^South San Francisco, California, May 10, 2025 (Globe Newswire) – Akero
Therapeutics, Inc. (Nasdaq: Akro), a clinical phase
Company that pioneering therapies for patients with serious
Metabolic diseases developed for which a high medical need
existed at the 2025 congress of the European Association for the Study of
The Liver (Easl), which takes place in Amsterdam, Netherlands from May 7th to May 10th
The results of the Symmetry phase IIB study, which the potential of Efruxifer appointment
(EFX) to improve fibrosis with compensated cirrhosis (F4), which through
caused by metabolic dysfunction of associated steatohepatitis (mash)
is presented.
? Compensated cirrhosis due to mash still places a high
Uncovered medical needs. The patients have a bad one
Forecast and currently no effective treatment options beyond the
Liver transplantation, “says Kitty Yale, Chief Development Officer from Akero.
? This data presented at the EASL congress 2025 differentiates EFX from
other approved or tested mash treatments, there
you are the first to reverse fibrosis in patients with cirrhosis
Show mash. We look forward to EFX in all stadiums from Mash in our
To further examine phase III program synchrony. “
? Patients with liver cirrhosis caused by mash have a 50-
Percentic chance, without liver transplant within five years too
die, “said Dr. Mazen Noureddin, Professor of Medicine and
Transplantation hepatologist at the Houston Methodist Hospital and senior test doctor
the symmetry study .? The strong antifibrotic effect of EFX, as
Phase-IIB study Symmetry was observed and is currently being examined in phase III
has the potential, the most important medical breakthrough in my
To be a career as a treating doctor.
The data presented from week 96 by Symmetry, a phase IIB study for
Evaluation of the effectiveness and security of the leading product candidate of
Akero, EFX, in patients with a bioptically confirmed compensated cirrhosis (F4)
Due to mash, both in the fullness and in the
Intent-to-Treat analysis (ITT) after 96 weeks a fibrosis reduction without
Detachment of the mash. In the predefined analysis of patients with
Biopsia at Baseline and in week 96 (n = 134) had 39 % of the one with EFX 50 mg
treated patients an improvement in fibrosis compared to 15 % of the MIT
Patients treated (p = 0.009). In the ITT population (n = 181) with
Missing biopsies in week 96, which were treated as non-responders, learned
29 % of the patients in the EFX 50mg group this improvement compared to 11
% with placebo (p = 0.031). The primary endpoint of the Symmetry study was one
Improvement of the fibrosis by> = 1 stage without worsening the mash in week
36. In week 36, a numerical one was in the EFX groups compared to placebo
Improvement observed, but the differences were not statistically
significant.
Summary of the fibrosis improvement in week 96 without mash deterioration
(secondary end point)
+———————————————————————–
| | Primary analysis (n = 134) (1) | ITT analysis (N = 181) (2) |
+———————–+——+———————————–+
| Histology endpoint (3) | Placebo | EFX 28 mg | EFX 50 mg | Placebo | EFX 28 mg | EFX 50 mg |
| (Painting of patients) | (n = 47) | (n = 41) | (n = 46) | (n = 61) | (n = 57) | (n = 63) |
+———————–+——+———————————–+
| Improvement of | | | | | | |
| Fibrose around> = 1 stage | 15 | 29 | 39 (**) | 11 | 21 | 29
|
| without worsening | | | | | | |
| The mash (%) | | | | | | |
+———————–+——+———————————–+
(1) All patients with biopsies at Baseline and in week 96
(2) The 47 randomized and treated patients, in which in week 96
Biopsia are missing, in ITT analysis (without imputation) as a non-responder
treated.
(3) The biopsies were evaluated independently by two pathologists;
A third was available for assessment (which was not necessary)
p â ° By the way: Akero Therapeutics and other US shares are even tradable at Finance.net Zero until 11 p.m. (without order fees, plus spreads).
Open Depot now for freeAnd receive a free stock as a gift.
ttn-28